This is a StreetInsider.com Premium Only Page

Syros Pharmaceuticals (SYRS) – StreetInsider.com Reports

Apr 9, 2024 07:07 AM Syros Pharmaceuticals (SYRS) Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpression

Mar 25, 2024 07:03 AM Syros Pharmaceuticals (SYRS) Completes Enrollment of 190 Patients Necessary to Support Primary Endpoint Analysis in SELECT-MDS-1 Phase 3 Trial

Dec 26, 2023 03:48 AM Syros Pharmaceuticals (SYRS) PT Lowered to $37 at Brookline Capital Markets

Dec 19, 2023 07:28 AM Syros Pharmaceuticals (SYRS) Prices $45M Share and Warrant Offering at $4.42/sh

Dec 6, 2023 07:03 AM Syros Pharmaceuticals (SYRS) Announces Encouraging Initial Data from Randomized SELECT-AML-1 Phase 2 Clinical Trial Evaluating Tamibarotene in Combination with Venetoclax and Azacitidine

Nov 14, 2023 07:33 AM Syros Pharmaceuticals (SYRS) Misses Q3 EPS by 29c

Oct 3, 2023 06:45 AM Syros Pharmaceuticals (SYRS) PT Lowered to $7 at Piper Sandler

Oct 2, 2023 08:45 AM Syros Pharmaceuticals (SYRS) Announces Planned CEO Leadership Transition and Strategic Reorganization

Aug 9, 2023 08:07 AM Syros Pharmaceuticals (SYRS) PT Lowered to $11 at Piper Sandler

Aug 8, 2023 07:32 AM Syros Pharmaceuticals (SYRS) Misses Q2 EPS by 17c, misses on revenue

May 25, 2023 05:07 PM Syros Pharmaceuticals (SYRS) Presents Data from Phase 1/1b Clinical Trial of SY-5609

May 11, 2023 02:36 AM Syros Pharmaceuticals (SYRS) PT Lowered to $15 at JMP Securities

Apr 6, 2023 04:50 PM Syros Pharmaceuticals (SYRS) files a $250 million mixed securities shelf

Mar 2, 2023 04:17 PM Syros Pharmaceuticals (SYRS) PT Lowered to $13 at Oppenheimer

Jan 26, 2023 07:05 AM Syros Pharmaceuticals (SYRS) Granted FDA Fast Track Designation for Tamibarotene

Jan 5, 2023 06:46 AM Syros Pharmaceuticals (SYRS) PT Lowered to $20 at Piper Sandler

Dec 12, 2022 07:32 AM Syros Pharmaceuticals (SYRS) Announces Publication in Blood Advances Demonstrating the Potential of Tamibarotene in Patients with RARA Gene Overexpression, Supporting Ongoing Clinical Development in A

Nov 15, 2022 07:42 AM Syros Pharmaceuticals (SYRS) PT Lowered to $15 at Oppenheimer

Nov 15, 2022 02:49 AM Syros Pharmaceuticals (SYRS) PT Lowered to $16 at JMP Securities

Nov 14, 2022 07:36 AM Syros Pharmaceuticals (SYRS) Tops Q3 EPS by 67c

Oct 14, 2022 04:36 PM Syros Pharmaceuticals (SYRS) Announces 27.63M Share Offering by Selling Stockholders

Sep 20, 2022 06:24 AM Syros Pharmaceuticals (SYRS) PT Lowered to $27 at Piper Sandler

Sep 15, 2022 04:02 PM Syros Pharmaceuticals (SYRS) and Tyme Technologies (TYME) Shareholders Approve Merger

Sep 13, 2022 04:01 PM Syros Pharmaceuticals (SYRS) Receives FDA Orphan Drug Designation for SY-5609 for the Treatment of Pancreatic Cancer

Sep 12, 2022 05:48 PM Syros Pharmaceuticals (SYRS) Granted FDA Orphan Drug Designation for Treatment of Pancreatic Cancer

Aug 10, 2022 04:51 AM Syros Pharmaceuticals (SYRS) PT Lowered to $3 at Oppenheimer

Aug 9, 2022 07:36 AM Syros Pharmaceuticals (SYRS) Misses Q2 EPS by 13c

Aug 3, 2022 04:03 PM Syros Pharmaceuticals (SYRS) Receives Positive Opinion on Orphan Drug Designation from the European Medicines Agency for Tamibarotene for the Treatment of MDS

Jul 5, 2022 07:02 AM Syros Pharmaceuticals (SYRS) to Raise Approximately $190 Million Through Merger with TYME Technologies (TYME) and Concurrent Private Placement

Jun 8, 2022 06:17 AM "There is Upside to Market Potential and Our Outlook" of SY-1425 - Brookline Capital Markets Bullish on Syros Pharmaceuticals (SYRS) with Buy Rating and $19 Price Target

May 17, 2022 06:44 AM Oppenheimer Reiterates Outperform Rating, $9 Price Target on Syros Pharmaceuticals (SYRS), "Investors Can Look Forward to Multiple Catalysts"

May 17, 2022 06:21 AM Syros Pharmaceuticals (SYRS) PT Lowered to $10 at H.C. Wainwright

May 16, 2022 07:31 AM Syros Pharmaceuticals (SYRS) Tops Q1 EPS by 7c

Apr 12, 2022 05:55 AM Syros Pharmaceuticals (SYRS) Reiterated at Buy by Brookline Capital Markets, Sees Additional Upside from CDK12

Mar 16, 2022 06:33 AM Oppenheimer Reiterates Outperform Rating on Syros Pharmaceuticals (SYRS), Sees Relatively Low Clinical Risk for SY-2101

Mar 15, 2022 07:33 AM Syros Pharmaceuticals (SYRS) Tops Q4 EPS by 9c

Feb 2, 2022 04:35 PM Syros Pharmaceuticals (SYRS) Confirms FDA Orphan Drug Designation for Tamibarotene for the Treatment of MDS

Feb 1, 2022 11:47 AM Syros Pharmaceuticals (SYRS) Receives FDA Orphan Drug Designation for Treatment of Myelodysplastic Syndrome (MDS)

Jan 11, 2022 09:06 AM Syros Pharmaceuticals (SYRS) PT Lowered to $10 at Piper Sandler

Jan 3, 2022 08:01 AM Syros Pharmaceuticals (SYRS) PT Raised to $23 at Brookline Capital Markets

Nov 5, 2021 07:36 AM Syros Pharmaceuticals (SYRS) Tops Q3 EPS by 3c; Reports Cash and Cash Equivalents of $166.7M

Oct 12, 2021 08:05 AM Syros Pharmaceuticals (SYRS) Appoints Jason Haas as CFO

Sep 23, 2021 08:27 AM UPDATE: Syros Pharmaceuticals (SYRS) PT Raised to $23 at Roth Capital

Sep 21, 2021 06:19 AM Syros Pharmaceuticals (SYRS) PT Lowered to $9 at Oppenheimer

Sep 10, 2021 07:34 AM Syros Pharmaceuticals (SYRS) Appoints Deborah Dunsire to its Board

Sep 7, 2021 07:26 AM Syros Pharmaceuticals (SYRS) PT Raised to $21 at Brookline Capital Markets

Aug 5, 2021 08:20 AM Syros Pharmaceuticals (SYRS) Tops Q2 EPS by 1c

Aug 5, 2021 07:20 AM Syros Pharmaceuticals (SYRS) Announces Agreement with Roche to Evaluate SY-5609 as Part of a Novel Combination for Treatment of Colorectal Cancer

May 6, 2021 07:51 AM Syros Pharmaceuticals (SYRS) Tops Q1 EPS by 23c, Revenues Beat

Mar 25, 2021 07:09 AM IMV Inc. (IMV) Names Kyle Kuvalanka to Board